NCT07075939Recruiting
Centralization and Oncologic Outcomes in Ovarian Cancer
Centralization and Oncologic Outcomes in Ovarian Cancer: A Multicenter Retrospective and Prospective Observational Study Within the REMO Network (COOC-REMO)
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia. The study aims to evaluate the impact of surgical centralization and treatment strategies adopted during the COVID-19 pandemic on oncologic outcomes in patients diagnosed with the epithelial ovarian cancer (EOC) from 2018 to 2023. The retrospective component includes patients treated between 2018 and 2023, while the prospective component consists of clinical follow-up of those patients over the next five years.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 11 Jul 2025
- Start date
- Jun 2025
- Primary completion date
- Jun 2030
- Lead sponsor
- Azienda USL Reggio Emilia - IRCCS
- Diseases
- Ovarian cancer
- NCT number
- NCT07075939
What you commit to
- Study type: Observational
- Planned participants: 200
- From Jun 2025 to the primary completion date, Jun 2030
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients without histological or cytological confirmation of epithelial ovarian cancer
- Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)
Other
- Incomplete or missing data for key clinical indicators
- Patients unable to provide informed consent and for whom recontact is not possible
Who the study is looking for
- Female patients aged between 18 and 99 years
- Histological and/or cytological diagnosis of epithelial ovarian cancer
- Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia
- Patients treated between January 1, 2018, and December 31, 2023
- Availability of clinical records and outcome data
- Signed informed consent where possible, in accordance with GDPR and Italian regulations
Age in the registry: 18 years to 99 years · Sex: Female · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda Unità - Sanitaria locale di Modena - Ospedale Razzini Carpi Coordinator of this site? Confirm its status | Carpi | Italy | Recruiting |
| Azienda Unità - Sanitaria locale di Modena - Ospedale di Mirandola Coordinator of this site? Confirm its status | Mirandola | Italy | Recruiting |
| Azienda Ospedaliero - Universitario di Modena Coordinator of this site? Confirm its status | Modena | Italy | Recruiting |
| Azienda Unità - Sanitaria locale di Modena - Ospedale Pavullo nel Frignano Coordinator of this site? Confirm its status | Pavullo nel Frignano | Italy | Not yet recruiting |
| Azienda USL IRCCS di Reggio Emilia Coordinator of this site? Confirm its status | Reggio Emilia | Italy | Recruiting |
| Azienda Unità - Sanitaria locale di Modena - Ospedale Civile Sassuolo Coordinator of this site? Confirm its status | Sassuolo | Italy | Recruiting |
| Azienda Unità - Sanitaria locale di Modena - Ospedale di Vignola Coordinator of this site? Confirm its status | Vignola | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.